MX2022015581A - 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. - Google Patents
2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.Info
- Publication number
- MX2022015581A MX2022015581A MX2022015581A MX2022015581A MX2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- disorders
- inhibitors
- prevention
- management
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- RFHFJIQWGQFZBX-UHFFFAOYSA-N 2-oxoimidazolidine-4-carboxamide Chemical class NC(=O)C1CNC(=O)N1 RFHFJIQWGQFZBX-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 108091006146 Channels Proteins 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Nuevos compuestos de la fórmula estructural (I), y las sales farmacéuticamente aceptables de los mismos, son inhibidores de la actividad de los canales Nav1.8 y pueden ser útiles en el tratamiento, prevención, gestión, mejoría, control y supresión de enfermedades mediadas por la actividad de los canales Nav1.8. Los compuestos de la presente invención pueden ser útiles en el tratamiento, prevención o gestión de trastornos de dolor, trastornos de tos, trastornos de picazón aguda y trastornos de picazón crónica. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063040461P | 2020-06-17 | 2020-06-17 | |
PCT/US2021/037303 WO2021257490A1 (en) | 2020-06-17 | 2021-06-15 | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015581A true MX2022015581A (es) | 2023-01-24 |
Family
ID=76829646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015581A MX2022015581A (es) | 2020-06-17 | 2021-06-15 | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. |
Country Status (19)
Country | Link |
---|---|
US (2) | US11802122B2 (es) |
EP (1) | EP4168393A1 (es) |
JP (3) | JP7323723B2 (es) |
KR (1) | KR20230024985A (es) |
CN (1) | CN116134018A (es) |
AR (1) | AR122628A1 (es) |
AU (1) | AU2021293176A1 (es) |
BR (1) | BR112022025805A2 (es) |
CA (1) | CA3182633A1 (es) |
CL (1) | CL2022003544A1 (es) |
CO (1) | CO2022018295A2 (es) |
CR (1) | CR20220642A (es) |
DO (1) | DOP2022000290A (es) |
EC (1) | ECSP23003443A (es) |
IL (1) | IL299180A (es) |
MX (1) | MX2022015581A (es) |
PE (1) | PE20231383A1 (es) |
TW (1) | TWI806073B (es) |
WO (1) | WO2021257490A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4334293A1 (en) * | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
CN117813302A (zh) | 2021-06-04 | 2024-04-02 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂 |
EP4347031A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
WO2022256708A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン |
EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010523524A (ja) | 2007-04-03 | 2010-07-15 | グラクソ グループ リミテッド | P2x7調節因子としてのイミダゾリジンカルボキサミド誘導体 |
KR20100066583A (ko) | 2007-10-11 | 2010-06-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압-개폐 나트륨 채널의 억제제로서 유용한 아미드 |
JP5555169B2 (ja) | 2007-10-11 | 2014-07-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド |
EP2212290B1 (en) | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
US8629149B2 (en) | 2009-09-04 | 2014-01-14 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
CA2839703A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
MX2013015274A (es) | 2011-06-24 | 2014-03-31 | Amgen Inc | Anatagonista trpm8 y su uso en tratamientos. |
US9139529B2 (en) | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
TWI659945B (zh) | 2013-01-31 | 2019-05-21 | 維泰克斯製藥公司 | 作爲鈉通道調節劑之醯胺 |
PL2953931T3 (pl) | 2013-01-31 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Pirydonoamidy jako modulatory kanałów sodowych |
WO2014146111A2 (en) * | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Analgesic compounds and methods of use |
US11203571B2 (en) | 2013-07-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
NZ760006A (en) | 2013-12-13 | 2022-07-29 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
EP3470404A1 (en) | 2016-05-31 | 2019-04-17 | Industry Academic Cooperation Foundation, Hallym University | Five-membered heterocyclic derivative, method for producing same, and pharmaceutical composition comprising same |
UA124857C2 (uk) | 2017-05-16 | 2021-12-01 | Вертекс Фармасьютикалз Інкорпорейтед | Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів |
PE20201164A1 (es) | 2017-07-11 | 2020-10-28 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
AU2018332887B2 (en) * | 2017-09-13 | 2022-12-08 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
CA3117927A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
-
2021
- 2021-06-15 JP JP2022577338A patent/JP7323723B2/ja active Active
- 2021-06-15 MX MX2022015581A patent/MX2022015581A/es unknown
- 2021-06-15 KR KR1020237001361A patent/KR20230024985A/ko active Search and Examination
- 2021-06-15 TW TW110121743A patent/TWI806073B/zh active
- 2021-06-15 CR CR20220642A patent/CR20220642A/es unknown
- 2021-06-15 PE PE2022002927A patent/PE20231383A1/es unknown
- 2021-06-15 AR ARP210101629A patent/AR122628A1/es unknown
- 2021-06-15 EP EP21739498.0A patent/EP4168393A1/en active Pending
- 2021-06-15 IL IL299180A patent/IL299180A/en unknown
- 2021-06-15 WO PCT/US2021/037303 patent/WO2021257490A1/en active Application Filing
- 2021-06-15 BR BR112022025805A patent/BR112022025805A2/pt unknown
- 2021-06-15 AU AU2021293176A patent/AU2021293176A1/en active Pending
- 2021-06-15 CN CN202180057478.6A patent/CN116134018A/zh active Pending
- 2021-06-15 US US17/347,639 patent/US11802122B2/en active Active
- 2021-06-15 CA CA3182633A patent/CA3182633A1/en active Pending
-
2022
- 2022-12-13 CL CL2022003544A patent/CL2022003544A1/es unknown
- 2022-12-15 CO CONC2022/0018295A patent/CO2022018295A2/es unknown
- 2022-12-15 DO DO2022000290A patent/DOP2022000290A/es unknown
-
2023
- 2023-01-16 EC ECSENADI20233443A patent/ECSP23003443A/es unknown
- 2023-04-19 JP JP2023068778A patent/JP2023093623A/ja active Pending
- 2023-06-05 US US18/329,108 patent/US20230312528A1/en active Pending
- 2023-07-27 JP JP2023122332A patent/JP2023139235A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DOP2022000290A (es) | 2023-01-31 |
WO2021257490A1 (en) | 2021-12-23 |
ECSP23003443A (es) | 2023-02-28 |
US20210403457A1 (en) | 2021-12-30 |
JP2023139235A (ja) | 2023-10-03 |
IL299180A (en) | 2023-02-01 |
CO2022018295A2 (es) | 2022-12-20 |
TW202214573A (zh) | 2022-04-16 |
US20230312528A1 (en) | 2023-10-05 |
BR112022025805A2 (pt) | 2023-01-10 |
EP4168393A1 (en) | 2023-04-26 |
CR20220642A (es) | 2023-02-15 |
JP2023093623A (ja) | 2023-07-04 |
US11802122B2 (en) | 2023-10-31 |
JP7323723B2 (ja) | 2023-08-08 |
CN116134018A (zh) | 2023-05-16 |
PE20231383A1 (es) | 2023-09-12 |
AU2021293176A1 (en) | 2023-02-02 |
TWI806073B (zh) | 2023-06-21 |
JP2023524167A (ja) | 2023-06-08 |
CA3182633A1 (en) | 2021-12-23 |
AR122628A1 (es) | 2022-09-21 |
KR20230024985A (ko) | 2023-02-21 |
CL2022003544A1 (es) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015581A (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. | |
MX2022015580A (es) | 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8. | |
MX2022015579A (es) | 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8. | |
ZA202102628B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
CR20230519A (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
MX2021010625A (es) | Derivado de pirazina y aplicacion del mismo en la inhibicion de shp2. | |
MX2023007192A (es) | Inhibidores de prmt5. | |
MX2022015857A (es) | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. | |
MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
BR112023023186A2 (pt) | 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8 | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
MX2021010870A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
MX2021010869A (es) | Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso. | |
PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
MY148565A (en) | Agent for therapy and/or improvement of disseminated intravascular coagulation | |
MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
MX2022013482A (es) | Compuestos utiles para inhibir la quinasa ret. | |
MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
WO2019066548A3 (ko) | 심부전의 예방 또는 치료용 약학적 조성물 | |
WO2023122325A3 (en) | Meta anilide compounds and methods for use of the same to treat diseases and disorders | |
WO2023122783A3 (en) | Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead | |
WO2019035646A8 (ko) | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 |